Real-Life Clinical Effectiveness of Razumab® (World’s First Biosimilar Ranibizumab) in Wet AgeRelated Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Retrospective Pooled Analysis
Journal Title: International Journal of Ophthalmology & Eye Science (IJOES) - Year 2018, Vol 6, Issue 4
Abstract
Purpose: To evaluate the effectiveness of Razumab® (world’s first biosimilar ranibizumab; Intas Pharmaceuticals Ltd., India) in Indian patients with wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO). Methods: RE-ENACT, a retrospective, multicenter study, analyzed pooled data of patients with wet AMD, DME, and RVO. Patients who had received ≥3 injections of Razumab® between January and August 2016, were included. Endpoints were: improvement in best corrected visual acuity (BCVA, measured by logMAR/Snellen’s chart), decrease in central macular thickness (CMT, measured by Spectral Domain Optical Coherence Tomography), and proportion of patients with intraretinal fluid (IRF) and subretinal fluid (SRF) at Weeks 4, 8 and 12. Results: Of 561 patients included, 348 (62.04%) were men. Mean ± SE BCVA improved from baseline (0.75 ± 0.01) to Week 4 (0.72 ± 0.01, p = 0.0318), attained significance at Week 8 (0.59 ± 0.01, p < 0.0001), which was maintained at Week 12 (0.49 ± 0.01, p < 0.0001). Mean ± SE CMT significantly (p < 0.0001) decreased from baseline (418.47 ± 4.78μm) to Weeks 4 (407.35 ± 4.65μm), 8 (342.10 ± 3.66μm), and 12 (301.17 ± 2.82μm). Proportion of patients with IRF and SRF significantly (p < 0.0001) decreased from baseline to Weeks 4, 8 and 12 (67.02% vs. 48.48%, 42.60%, and 34.22%, respectively for IRF; and 72.37% vs. 48.48%, 37.97%, 31.37%, respectively for SRF). No new safety concerns with biosimilar ranibizumab were observed. Conclusions: Razumab® is effective in reducing macular thickness and improving visual acuity in patients with wet agerelated macular degeneration, diabetic macular edema, and retinal vein occlusion in routine clinical practice. Razumab® demonstrated considerable effectiveness with no new safety concerns.
Authors and Affiliations
Dr. Shashikant Sharma
Keywords
Related Articles
- EP ID EP532977
- DOI 10.19070/2332-290X-1800076
- Views 58
- Downloads 0
Daylight For Healthy Indoor Environment And Energy Benefits
Daylight For Healthy Indoor Environment And Energy Benefits
Modified Osteo Odonto Keratoprosthesis (MOOKP) - "Tooth For An Eye"
Osteo-odonto-keratoprosthesis (OOKP) (also known as "tooth in eye" surgery is a medical procedure to restore vision in the most severe cases of corneal and ocular surface patients. It includes removal of a tooth from the...
Retinopathy of Prematurity: Incidence and Risk Factors
Background: With improved neonatal care services across India, even the tiniest and sickest babies are surviving. However,they carry a high chance of developing retinopathy of prematurity (ROP). Therefore, pediatricians...
Manual Small Incisional Cataract Surgery Learning Curve: Observational Comparison of Three Trainee Training
Purpose: To assess and compare the learning curve of three ophthalmology trainee in their post graduate training for Manual Small Incisional Cataract Surgery (MSICS) over 50 cases each. Methods: The study was done over...
Successful Management of a Patient with Florid Diabetic Retinopathy
Florid diabetic retinopathy is an unusual, aggressive type of diabetic retinopathy. It is seen in young patients with poor metabolic control. Despite advances in treatment the overall prognosis of this condition remains...